Search results for JMJD2A antibody

JMJD2A antibody, Covalab, Ref 00101127

KDM4A/JHDM3A/JMJD2A Antibody (YA4928), MedChemexpress, HY-P85236

KDM4A/JHDM3A/JMJD2A Antibody (YA4928) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to KDM4A/JHDM3A/JMJD2A.

KDM4A/JHDM3A/JMJD2A Antibody (YA3331), MedChemexpress, HY-P83586

KDM4A/JHDM3A/JMJD2A Antibody (YA3331) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to KDM4A/JHDM3A/JMJD2A.

Anti-JMJD2A Antibody (N154/30), AntibodySystem, RHB11504

Anti-JMJD2A Antibody (N154/32), AntibodySystem, RHB11502

Anti-JMJD2A Antibody (N154/37), AntibodySystem, RHB11503

Anti-KDM4A / JHDM3A / JMJD2A antibody [EPR18466], Abcam, AB191433

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

PE Anti-KDM4A / JHDM3A / JMJD2A antibody [EPR18466], Abcam, AB318346

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

APC Anti-KDM4A / JHDM3A / JMJD2A antibody [EPR18466], Abcam, AB318449

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

KDM4A/JHDM3A/JMJD2A Antibody (YA3331)(PBS only), MedChemexpress, HY-P83586A

KDM4A/JHDM3A/JMJD2A Antibody (YA3331) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to KDM4A/JHDM3A/JMJD2A.